盐酸达拉他韦联合阿舒瑞韦对代偿期丙型肝炎肝硬化患者肾功能的影响

梁志军; 王素娜

doi:10.3969/j.issn.1001-5256.2018.07.014

盐酸达拉他韦联合阿舒瑞韦对代偿期丙型肝炎肝硬化患者肾功能的影响

DOI: 10.3969/j.issn.1001-5256.2018.07.014

1. 第四军医大学唐都医院传染科
2. 西安医学高等专科学校附属医院感染科

详细信息

中图分类号: R512.63;R575.2
计量
- 文章访问数: 2107
- HTML全文浏览量: 3
- PDF下载量: 393
- 被引次数: 0
出版历程
- 收稿日期: 2017-10-19
- 出版日期: 2018-07-20

Influence of daclatasvir hydrochloride combined with asunaprevir on renal function in patients with compensated hepatitis C cirrhosis

Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University

摘要

摘要: 目的观察盐酸达拉他韦抗病毒联合阿舒瑞韦抗病毒治疗对代偿期丙型肝炎肝硬化患者肾功能的影响。方法纳入2017年5月-2017年9月在第四军医大学唐都医院传染科就诊的HCV基因1b型感染所致的代偿期丙型肝炎肝硬化初治患者44例,所有患者均接受盐酸达拉他韦（60 mg,1次/d）联合阿舒瑞韦（100 mg,2次/d）口服抗病毒治疗,疗程24周。比较基线、治疗4周和24周时患者HCV RNA阴转率、ALT复常率、尿素氮、肌酐和估算肾小球滤过率（eGFR）的变化。其中eGFR分别采用简化的肾脏病饮食改良（MDRD）和慢性肾脏病流行病学合作研究（CKD-EPI）两种方法进行计算。对于符合正态分布的计量资料组间比较采用方差分析,进一步两两比较采用SNK-q检验。结果治疗24周时患者的HCV RNA阴转率和ALT复常率分别为100%（44/44）和97.50%（39/40）。治疗过程中,患者尿素氮水平在24周[（4.91±1.41）mmol/L]较基线[（4.43±1.09）mmol/L]显著升高,差异具有统计学意义（q=2.322,P=0.025）。但患者肌酐水平在治疗4周和24周时与基线比较差异均无...
- 肝炎,丙型 /
- 肝硬化 /
- 肾功能试验 /
- 抗病毒药
Abstract: Objective To investigate the influence of daclatasvir hydrochloride combined with asunaprevir on renal function in patients with compensated hepatitis C cirrhosis. Methods A total of 44 previously untreated patients with compensated hepatitis C cirrhosis caused by hepatitis C virus genotype 1 b infection who visited Department of Infectious Diseases in Tangdu Hospital, Fourth Military Medical University, from May 2017 to September 2017 were enrolled. All patients were given oral daclatasvir hydrochloride ( 60 mg, once a day) combined with asunaprevir ( 100 mg, twice a day) as the antiviral therapy, and the course of treatment was 24 weeks. The changes in HCV RNA clearance rate, alanine aminotransferase ( ALT) normalization rate, blood urea nitrogen, creatinine, and estimated glomerular filtration rate ( eGFR) were measured from baseline to weeks 4 and 24 of treatment were observed, and eGFR was calculated using the Modification of Diet In Renal Disease ( MDRD) and Chronic Kidney Disease Epidemiology Collaboration ( CKD-EPI) equations. The chi-squared test was used for comparison of normally distributed continuous data between groups, and the SNK-q test was used for further comparison between two groups. Results At week 24 of treatment, the HCV RNA clearance rate was 100% ( 44/44) and the ALT normalization was 97. 50% ( 39/40) . There was a significant increase in blood urea nitrogen from baseline ( 4. 43 ± 1. 09 mmol/L) to week 24 of treatment ( 4. 91 ± 1. 41 mmol/L) ( q = 2. 322, P = 0. 025) , while there was no significant change in creatinine from baseline to week 4 or 24 of treatment ( both P> 0. 05) . There was no significant change in eGFR calculated using either MDRD or CKD-EPI equation from baseline to week 4 or 24 of treatment ( both P > 0. 05) . As for the 14 patients with a baseline eGFR of < 90 ml/min/1. 73 m2 calculated using the MDRD equation, they had a significant increase in eGFR from baseline ( 82. 81 ± 7. 16 ml/min/1. 73 m2) to week 24 of treatment ( 89. 65 ± 15. 85 ml/min/1. 73 m2) ( q = 2. 303, P = 0. 038) . Conclusion Daclatasvir hydrochloride combined with asunaprevir has no significant influence on renal function in patients with compensated hepatitis C cirrhosis, and there is a need for more studies with a large sample size.
- hepatitis C /
- liver cirrhosis /
- kidney function tests /
- antiviral agents

HTML全文

参考文献(19)

[1]NEGRO F, FORTON D, CRAXIA, et al.Extrahepatic morbidity and mortality of chronic hepatitis C[J].Gastroenterology, 2015, 149 (6) :1345-1360.

[2]DONATO MF, FABRIZI F, FOGAZZI GB, et al.Remission of HCVassociated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation:Case report and literature review[J].Int J Artif Organs, 2013, 36 (1) :63-68.

[3]PENG MJ, WANG W, YANG XF, et al.Influence of pegylated interferonα-2a versus telbivudine on renal function in patients with chronic hepatitis B[J].J Clin Hepatol, 2016, 32 (4) :682-686. (in Chinese) 彭梅娟, 王伟, 杨晓飞, 等.聚乙二醇干扰素α-2a与替比夫定对慢性乙型肝炎患者肾功能影响的比较[J].临床肝胆病杂志, 2016, 32 (4) :682-686.

[4]LEVEY AS, BOSCH JP, LEWIS JB, et al.A more accurate method to estimate glomerular filtration rate from serum creatinine:A new prediction equation.Modification of Diet in Renal Disease Study Group[J].Ann Intern Med, 1999, 130 (6) :461-470.

[5]LEVEY AS, STEVENS LA, SCHMID CH, et al.A new equation to estimate glomerular filtration rate[J].Ann Intern Med, 2009, 150 (9) :604-612.

[6]MENDIZABAL M, REDDY KR.Chronic hepatitis C and chronic kidney disease:Advances, limitations and unchartered territories[J].J Viral Hepat, 2017, 24 (6) :442-453.

[7]SHO T, SUDA G, NAGASAKA A, et al.Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction[J].Hepatol Res, 2018.[Epub ahead of print]

[8]KONG WL, YANG YL, XU HQ, et al.Relationship between liver function and virological response in patients with chronic hepatitis C during antiviral treatment[J].J Jilin Univ:Med Edit, 2016, 42 (1) :99-103. (in Chinese) 孔文丽, 杨以良, 徐洪芹, 等.慢性丙型肝炎患者抗病毒治疗中肝功能与病毒学应答的关系[J].吉林大学学报:医学版, 2016, 42 (1) :99-103.

[9]ZHANG Y, ZHANG WL, PANG XW, et al.Effect of 48-week pegylated interferonα-2a or nucleos (t) ide analogue therapy on renal function in Chinese patients with chronic hepatitis B[J].Virol J, 2017, 14 (1) :49.

[10]JADOUL M, MARTIN P.Hepatitis C treatment in chronic kidney disease patients:The kidney disease improving global outcomes perspective[J].Blood Purif, 2017, 43 (1-3) :206-209.

[11]BUNCHORNTAVAKUL C, MANEERATTANAPORN M, CHAVALITDHAMRONG D.Management of patients with hepatitis C infection and renal disease[J].World J Hepatol, 2015, 7 (2) :213-225.

[12]KHATRI A, DUTTA S, MARBURY TC, et al.Pharmacokinetics and tolerability of anti-hepatitis C virus treatment with ombitasvir, paritaprevir, ritonavir, with or without dasabuvir, in subjects with renal impairment[J].Clin Pharmacokinet, 2017, 56 (2) :153-163.

[13]ABAD S, VEGA A, HERNANDEZ E, et al.Universal sustained viral response to the combination of ombitasvir/paritaprevir/ritonavir and dasabuvir with/without ribavirin in patients on hemodialysis infected with hepatitis C virus genotypes 1 and 4[J].Am J Nephrol, 2017, 45 (3) :267-272.

[14]TOYODA H, KUMADA T, TADA T, et al.Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis[J].J Gastroenterol, 2016, 51 (7) :741-747.

[15]MIYAZAKI R, MIYAGI K.Effect and safety of daclatasvir-asunaprevir combination therapy for chronic hepatitis C virus genotype1b-infected patients on hemodialysis[J].Ther Apher Dial, 2016, 20 (5) :462-467.

[16]KAWAKAMI Y, IMAMURA M, IKEDA H, et al.Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C:Pilot study[J].J Viral Hepat, 2016, 23 (11) :850-856.

[17]SUDA G, NAGASAKA A, YAMAMOTO Y, et al.Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment[J].Hepatol Res, 2017, 47 (11) :1127-1136.

[18]NAKAMURA Y, IMAMURA M, KAWAKAMI Y, et al.Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction[J].J Med Virol, 2017, 89 (4) :665-671.

[19]MORISAWA N, KOSHIMA Y, SATOH JI, et al.Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease[J].Clin Exp Nephrol, 2017, 21 (5) :818-824.

施引文献

资源附件(0)

访问统计